Skip to main content
RAPS Convergence 2023 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Requires Pre-Registration or Sign-up
Requires Pre-Registration or Sign-up
Additional Registration Fee
Additional Registration Fee
Invitation Only
Invitation Only
Student Program
Student Program
Networking Opportunity
Networking Opportunity
RAPS Focus Area
RAPS Focus Area
Back

Myriam Triest, PhD

Vice-President
CMC-RX Consulting, Canada

Myriam Triest, PhD, is the Vice-President at CMC-Rx Consultancy. CMC-RX specializes in the technical and operational management of CMC activities that lead to the authoring of robust regulatory submissions & technical files for Investigational (IND), New Drug Applications (NDA) and Clinical Trial Applications (CTA).
As Senior Director Technical Operations at Appili Therapeutics, an infectious disease company, Myriam Triest worked on several US Department of Defence supported projects: she planned the development of a live-vaccine including outsourcing to the Pilot Bioproduction Facility at Walter-Reed, oversaw the change in manufacturer of the anti-leishmania cream prior to filing the NDA. During the pandemic, she was responsible for establishing the commercial supply chain of a potential Covid-19 drug and preparing the CMC Module 3 for a FDA Emergency Use Authorization.

Previous to that, Myriam Triest was the CMC lead at Locemia Solutions for the development of intra-nasal glucagon. She managed this combination drug product, from initial lab experiments to a successful phase III.

Disclosure information not submitted.

Presentation(s):